caly .. heiss!

Seite 1 von 1
neuester Beitrag: 18.09.03 17:30
eröffnet am: 18.09.03 17:30 von: gueler Anzahl Beiträge: 1
neuester Beitrag: 18.09.03 17:30 von: gueler Leser gesamt: 2347
davon Heute: 1
bewertet mit 0 Sternen

18.09.03 17:30

395 Postings, 7339 Tage guelercaly .. heiss!

Company News and Press Releases From Other Sources:

Nationally Recognized Analyst Picks Hot OTC Stock!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Wall Street Capital Funding.

WESTON, FL, Sep. 18, 2003 (MARKET WIRE via COMTEX) -- Wall Street News Alert's "stocks to watch" this morning are: Amarillo Biosciences Incorporated (OTC BB: AMAR), Citigroup Inc. (NYSE: C), Calypte Biomedical (OTC BB: CYPT) and NVIDIA Corporation (NASDAQ: NVDA).
Watch Amarillo Biosciences, Inc. (OTC BB: AMAR) stock for a potential move this morning! J. David Stewart, a nationally recognized analyst who has been the focus of feature stories in Money magazine, FORTUNE and Entrepreneur, featured the company as his TOP PICK on AGRO-TERRORISM ( Stewart, whose web site boast impressive percentage gains for the stocks that he follows, expresses concerns over America's livestock and their vulnarability to attacks by agro-terrorists. He states that the government's current proposed response to the introduction of foreign animal diseases such as foot-and-mouth disease (FMD) is to depopulate affected and exposed animals (animals, which are not infected with FMD, but have been in contact with infected animals). Depopulation could involve the slaughter of millions of animals, with the carcasses disposed of by burning, composting, rendering or burial -- a process that could cost billions of dollars.

According to Stewart, Amarillo has a solution to Depopulation, involving the company's 18 patents on the use of oral interferon introduced into livestock feed as a stimulus to improve the animals' ability to resist FMD infection. Furthermore, CDAD (Committee to Develop an Alternative of Depopulation) will be presenting itself to almost all areas of Defense. "CDAD" is composed of industry, university and government experts on epidemiology, immunology, animal nutrition, virology, biostatistics, pathology and animal production. David Stewart believes their cumulative presence could be impactful of world events. Dr. Joseph Cummins, President of Amarillio Biosciences, recently announced the formation of CDAD to prepare possible government responses in the event foreign animal diseases are introduced into the U.S. livestock industry.

Stocks showing interesting activity yesterday were: Citigroup Inc. (NYSE: C) up .54% on 13.3 million shares traded, Calypte Biomedical Corp (OTC BB: CYPT) down 7.8% on 9.8 million shares traded and NVIDIA Corporation (NASDAQ: NVDA) up 1.1% on 7.5 million shares traded.

Commentary: Ways to cut drug costs

"Many suggestions have come along to help cut drug costs besides going to Canada or Mexico. One is to ask your doctor for a generic brand, if one exists. If you would rather do the research yourself before you go to the doctor check out these sites: 1); type in the name or check out the generic information. 2) or and type in key word generic. 3) At, a website set up by the Pharmaceutical and Research and Manufacturers of America, the site steers people to patient assistance programs. 4) and are also information sites to help you look at your medications and prices," Stated Sonja Rudd in Wall Street News Alert's daily commentary continued at:

WSNA's email alert service is free to those investors who sign up on the WSNA home page. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to Special Situation companies that have the potential of showing increased activity. The Wall Street News Alert home page has experienced over 7.5 million hits. To subscribe to this free service, visit the Wall Street News Alert home page at and select the "join now" button.

Verify all claims and do your own due diligence. Wall Street News Alert is a division of Wall Street Capital Funding LLC (WSCF). WSCF profiles are not a solicitation or recommendation to buy, sell or hold securities. WSCF is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of WSCF and are subject to change without notice. The companies that are discussed in this opinion have not approved the statements made in this opinion. This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. This profile is not without bias, and is a paid advertisement. WSCF is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained in WSCF profiles is provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment if they make a purchase in WSCF profiled stocks. WSCF has been compensated on behalf of one or more of the companies mentioned in this opinion. (WSNA has been compensated Seventeen Thousand and Five Hundred Dollars for coverage of Amarillo Biosciences, Inc. (OTC BB: AMAR), by a third party (J. David Stewart), who is non-affiliated, for services provided including this advertisement.) WSCF does not own any of the company's stock. WSCF will not advise as to when others should sell; each investor must make that decision. Market commentary provided by Sonja Rudd.

   Antwort einfügen - nach oben